Loading…
Acurx Pharmaceuticals, Inc. is projected to rise to $1.45 by 2027, a +2% move from its current price of $1.43. ACXP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.38 | $1.43 | $1.48 | +0.01% |
| Aug 6 | $1.36 | $1.43 | $1.50 | +0.01% |
| Aug 7 | $1.35 | $1.43 | $1.52 | +0.02% |
| Aug 8 | $1.33 | $1.43 | $1.53 | +0.02% |
| Aug 9 | $1.32 | $1.43 | $1.55 | +0.03% |
| Aug 10 | $1.31 | $1.43 | $1.56 | +0.04% |
| Aug 11 | $1.30 | $1.43 | $1.57 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.30 | $1.43 | $1.57 | +0.04% |
| Week 2 | $1.26 | $1.43 | $1.63 | +0.09% |
| Week 3 | $1.22 | $1.43 | $1.68 | +0.13% |
| Week 4 | $1.19 | $1.43 | $1.72 | +0.17% |
| Week 5 | $1.16 | $1.43 | $1.76 | +0.21% |
| Week 6 | $1.14 | $1.43 | $1.80 | +0.26% |
| Week 7 | $1.12 | $1.43 | $1.83 | +0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company in Healthcare that develops antibiotics to treat bacterial infections in the United States.
Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc.
was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc. trades as ACXP and has a current price of $1.47 per share with a market capitalization of $6.32M and a rank of 5034.
The stock’s current price sits in a low market-cap segment, and the near-term trajectory is described as neutral based on available forecasts. The company’s stated focus is on developing antibiotics to treat bacterial infections in the United States, with ibezapolstat in Phase 2b and ACX-375C targeting a range of gram-positive bacteria.
A major floor 21.2% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 22.4% above — a clean break opens room to run.
A major ceiling 199.3% above — clearing it would confirm fresh momentum.
Key ACXP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACXP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.42 | Buy | $1.43 | Buy |
| MA 10 | $1.45 | Sell | $1.45 | Sell |
| MA 20 | $1.50 | Sell | $1.49 | Sell |
| MA 50 | $1.61 | Sell | $1.68 | Sell |
| MA 100 | $2.35 | Sell | $2.10 | Sell |
| MA 200 | $2.95 | Sell | $3.66 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.27 | Neutral |
| Stoch RSI (14) | 24.16 | Neutral |
| CCI (20) | -49.78 | Neutral |
| Williams %R (14) | -86.11 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -17.71 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 13.89 | Buy |
| TRIX (15) | -0.45 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 40.66 | Neutral |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 1.40 | Buy |
| ADX (14) | 17.36 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 40.
The stock trades below its 50-day simple moving average of $1.69 and well below its 200-day simple moving average of $3.11.
Support is at $1.36 and resistance at $1.75, with a 30-day price range of $1.11 to $1.94.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $1.43 | $1.87 | 0% | Neutral | |
| $1.13 | $1.45 | $1.99 | +2% | Neutral | |
| $1.02 | $1.36 | $1.96 | -5% | Neutral | |
| $1.02 | $1.41 | $2.09 | -2% | Neutral | |
| $0.9263 | $1.31 | $2.01 | -8% | Neutral | |
| $0.8755 | $1.27 | $2.00 | -11% | Neutral | |
| $1.13 | $1.69 | $2.72 | +18% | Neutral | |
| $1.19 | $1.81 | $2.98 | +26% | Bullish | |
| $1.14 | $1.77 | $2.97 | +24% | Bullish | |
| $1.16 | $1.83 | $3.13 | +28% | Bullish | |
| $1.44 | $2.51 | $4.62 | +76% | Bullish | |
| $1.66 | $3.42 | $6.98 | +139% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.35 | $1.43 | $1.80 | +0.00% |
| September 2026 | $1.24 | $1.48 | $1.82 | +3.61% |
| October 2026 | $1.20 | $1.44 | $1.79 | -2.95% |
| November 2026 | $1.20 | $1.46 | $1.84 | +1.46% |
| December 2026 | $1.20 | $1.46 | $1.87 | +0.41% |
Click any year to see its month-by-month ACXP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ACXP is projected to trade between $1.35 and $1.87, averaging $1.43 — a potential gain of 0% from today's $1.43. A consolidation phase looks the most probable path here.
Acurx Pharmaceuticals, Inc.'s 2027 outlook centres on $1.45, within a $1.13 to $1.99 range. That is up +2% on the projected 2026 average. That marks a +2% change versus current levels. Price action looks broadly range-bound.
By 2028, ACXP could reach as high as $1.96, with a base case around $1.36 and support toward $1.02 — roughly -5% from $1.43. A consolidation phase looks the most probable path here.
Expect ACXP to range from $1.02 to $2.09 through 2029. The $1.41 average target implies a -2% move from current prices. That is up +3% on the projected 2028 average. Price action looks broadly range-bound.
The ACXP price prediction for 2030 points to an average of $1.31 (low $0.9263, high $2.01) — a potential decline of -8% on today's $1.43. A consolidation phase looks the most probable path here.
In 2031, ACXP is projected to trade between $0.8755 and $2.00, averaging $1.27 — a potential decline of -11% from today's $1.43. That is -3% versus the projected 2030 average. Price action looks broadly range-bound.
Acurx Pharmaceuticals, Inc.'s 2032 outlook centres on $1.69, within a $1.13 to $2.72 range. That is up +33% on the projected 2031 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, ACXP could reach as high as $2.98, with a base case around $1.81 and support toward $1.19 — roughly +26% from $1.43. Momentum favours further upside here.
Expect ACXP to range from $1.14 to $2.97 through 2034. The $1.77 average target implies a +24% move from current prices. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The ACXP price prediction for 2035 points to an average of $1.83 (low $1.16, high $3.13) — a potential gain of +28% on today's $1.43. Momentum favours further upside here.
In 2040, ACXP is projected to trade between $1.44 and $4.62, averaging $2.51 — a potential gain of +76% from today's $1.43. That is up +37% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Acurx Pharmaceuticals, Inc.'s 2050 outlook centres on $3.42, within a $1.66 to $6.98 range. That is up +36% on the projected 2040 average. That marks a +139% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ACXP today (≈ 699.300699 ACXP) could be worth
$2,390.45
+$1,390.45 (+139%) by 2050 · US Dollar
Based on the average projected ACXP price of $3.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACXPwould be worth at today's price.
$1,000 invested in ACXP on Jul 31, 2025 (≈ 153.374234 ACXP) would be worth
$219.33
-$780.67 (-78.1%) today · 0.22× · US Dollar
Based on a ACXP entry price of $6.52 vs. today's $1.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.42 | $1,007.04 | +0.7% |
| 1 month ago | $1.53 | $934.64 | -6.5% |
| 3 months ago | $2.16 | $662.04 | -33.8% |
| 6 months ago | $2.38 | $600.84 | -39.9% |
| 1 year ago | $6.52 | $219.33 | -78.1% |
| All time (5.0y) ago | $97.8 | $14.62 | -98.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACXP forecast.
Our base-case forecast reaches $2.90 around 2050.
Implied market cap at $2.90: $12.46M
The multi-year forecast shows a neutral to bullish trajectory across the horizon, with the average price stepping higher in later years and notable upside in the far future.
From 2026 through 2031, the average prices are in the roughly $1.28–$1.48 range, with near-term momentum remaining neutral and some years showing modest gains (e.g., 2027 avg $1.48, 2026 avg $1.47). The forecast includes negative ROIs in 2030 (-12.9%) and 2031 (-13.2%), reflecting near-term risk.
In 2032 the average rises to $1.73 with a 17.4% ROI, and 2033–2035 show stronger gains (2033 avg $1.87, ROI 27%; 2034 avg $1.82, ROI 24.1%; 2035 avg $1.84, ROI 25.2%), signaling a bullish tilt entering the mid-2030s.
The outlook continues to strengthen into the latter years, with 2040 averaging $2.65 and an 80.4% ROI, and 2050 averaging $3.28 with a 123.1% ROI. These are estimates, not guarantees, and reflect potential upside as the forecast horizon extends, alongside substantial uncertainty and risk.
Tap a question to reveal the answer.
2030: min $0.8607, avg $1.28, max $2.06; ROI -12.9%.
The data show a mix of neutral years early (e.g., 2026–2031) and bullish years later (2032–2050) with higher potential returns in 2040 and 2050 (2040 avg $2.65, ROI 80.4%; 2050 avg $3.28, ROI 123.1%). These are estimates and not guarantees, and risks remain.
The 2050 max forecast is $7.28, so a reach above $5 is possible according to the forecast, but it remains uncertain and not guaranteed.
Current price: $1.47. Market cap: $6.32M.
2040: min $1.36, avg $2.65, max $5.24; ROI 80.4%.
Acurx Pharmaceuticals, Inc. Community Discussion
0Share your Acurx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.